Personalized medicine
- PMID: 12596356
Personalized medicine
Abstract
Personalized medicine simply means the prescription of specific therapeutics best suited for an individual based on pharmacogenetic and pharmacogenomic information. The basis of personalized medicine are reviewed. Several technologies are used including single nucleotide polymorphism genotyping. haplotyping, gene expression studies by biochip/microarrays and proteomics. Molecular diagnostics will play an important role in the development of personalized medicine, in which therapy and diagnosis will be integrated. There are several examples of the personalized medical approach, which include genotype-based selection of patients for effective cancer therapy, to spare those who would not respond or would suffer undesirable side effects. Personalized therapy is financially feasible, as it will reduce the costs of drug development by shortening the drug development cycle. The introduction of pharmacogenomics into clinical trials is reducing the chances of failed clinical trials and increasing the prospects of safer and more effective therapies for specific groups of patients. Several advantages, as well as challenges to the development of personalized medicine are examined. Personalized medicine is anticipated to be an acceptable part of medical practice by the year 2010.
Similar articles
-
Assessing patient readiness for the clinical adoption of personalized medicine.Public Health Genomics. 2009;12(3):163-9. doi: 10.1159/000189629. Epub 2009 Feb 10. Public Health Genomics. 2009. PMID: 19204419
-
Personalized medicine: elusive dream or imminent reality?Clin Pharmacol Ther. 2007 Jun;81(6):807-16. doi: 10.1038/sj.clpt.6100204. Clin Pharmacol Ther. 2007. PMID: 17505496
-
Getting to personalized cancer medicine: taking out the garbage.Cancer. 2007 Oct 15;110(8):1641-3. doi: 10.1002/cncr.22966. Cancer. 2007. PMID: 17763370 No abstract available.
-
The current status and future potential of personalized diagnostics: Streamlining a customized process.Biotechnol Annu Rev. 2008;14:411-22. doi: 10.1016/S1387-2656(08)00015-X. Biotechnol Annu Rev. 2008. PMID: 18606372 Review.
-
Implications of pharmacogenomics for drug development and clinical practice.Arch Intern Med. 2005 Nov 14;165(20):2331-6. doi: 10.1001/archinte.165.20.2331. Arch Intern Med. 2005. PMID: 16287761 Review.
Cited by
-
Understanding Personalized Medicine in Rheumatoid Arthritis: A Clinician's Guide to the Future.Ther Adv Musculoskelet Dis. 2009 Apr;1(2):97-105. doi: 10.1177/1759720X09351778. Ther Adv Musculoskelet Dis. 2009. PMID: 22870431 Free PMC article.
-
Role of Biomarkers in the Clinical Management of Glioblastomas: What are the Barriers and How Can We Overcome Them?Front Neurol. 2013 Jan 18;3:188. doi: 10.3389/fneur.2012.00188. eCollection 2012. Front Neurol. 2013. PMID: 23346075 Free PMC article.
-
Molecular imaging will replace myocardial perfusion imaging.J Nucl Cardiol. 2008 May-Jun;15(3):429-34. doi: 10.1016/j.nuclcard.2008.04.002. J Nucl Cardiol. 2008. PMID: 18513649 Review. No abstract available.
-
Iranian-Islamic traditional medicine: An ancient comprehensive personalized medicine.Adv Biomed Res. 2015 Sep 28;4:191. doi: 10.4103/2277-9175.166151. eCollection 2015. Adv Biomed Res. 2015. PMID: 26605230 Free PMC article. Review.
-
An argument for renewed focus on epidemiology for public health.Ann Epidemiol. 2016 Oct;26(10):729-733. doi: 10.1016/j.annepidem.2016.08.008. Epub 2016 Aug 31. Ann Epidemiol. 2016. PMID: 27659585 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Other Literature Sources